Ensysce Biosciences is a shell companies business based in the US. Ensysce Biosciences shares (LACQ) are listed on the PINK and all prices are listed in US Dollars.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $13.97 |
| 200-day moving average | $13.65 |
| Wall St. target price | N/A |
| PE ratio | 118.7705 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.12 |
Valuing Ensysce Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ensysce Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ensysce Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 119x. In other words, Ensysce Biosciences shares trade at around 119x recent earnings.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -1.25% |
| Return on equity TTM | 23.4% |
| Profit margin | 0% |
| Book value | $0.30 |
| Market Capitalization | $90.2 million |
TTM: trailing 12 months
We're not expecting Ensysce Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Ensysce Biosciences's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Ensysce Biosciences's is -0.1134. This would suggest that Ensysce Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Ensysce Biosciences has bucked the trend.
Ensysce Biosciences, Inc. operates as a biotechnology company that develops abuse-resistant drug technologies. It offers TAAP, a trypsin-activated abuse protection technology that prevents abuse through a two-step internal trypsin-activation process to meet the medical needs of patients living with chronic pain; and MPAR, a multi-pill abuse resistant technology that provides a layer of protection for overdose. The company was incorporated in 2003 and is based in La Jolla, California. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.